{"id":17739,"date":"2020-12-23T10:00:38","date_gmt":"2020-12-23T08:00:38","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=17739"},"modified":"2020-12-23T10:00:38","modified_gmt":"2020-12-23T08:00:38","slug":"nuspresta-lietuva-isigis-papildomu-vakcinos-doziu-nuo-koronaviruso","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/2020\/12\/23\/nuspresta-lietuva-isigis-papildomu-vakcinos-doziu-nuo-koronaviruso\/","title":{"rendered":"Nuspr\u0119sta: Lietuva \u012fsigis papildom\u0173 vakcinos dozi\u0173 nuo koronaviruso"},"content":{"rendered":"<p><span lang=\"LT\">Antradien\u012f vakare<\/span> Vyriausyb\u0117s pasitarime nuspr\u0119sta papildomai \u012fsigyti vakcin\u0173 nuo <span lang=\"LT\">koronaviruso (<\/span>COVID-19 ligos<span lang=\"LT\">)<\/span>. Lietuva papildomai \u012fsigis <span lang=\"EN-US\">616 t<\/span><span lang=\"LT\">\u016bkst. vakcinos dozi\u0173.<\/span><\/p>\n<p><span lang=\"LT\">Europos Komisija pateik\u0117 pasi\u016blym\u0105 valstyb\u0117ms \u012fsigyti papildom\u0105 <\/span>Vokietijos farmacijos kompanijos \u201eBioNTech\u201c ir jos JAV partner\u0117s \u201ePfizer\u201c vakcin\u0173 dozi\u0173 <span lang=\"LT\">kiek\u012f. <\/span>Kiekvienai valstybei nar<span lang=\"LT\">ei<\/span> tenkantis kiekis nustatomas <span lang=\"LT\">pagal vadinam\u0105j\u012f pro<\/span> rata <span lang=\"LT\">princip\u0105<\/span>. Pagal \u0161\u012f metod\u0105 Lietuva <span lang=\"LT\">\u012fgijo galimyb\u0119 \u012fsigyti<\/span> 616 <span lang=\"LT\">t\u016bkst. <\/span>papildom\u0173 vakcinos dozi\u0173.<\/p>\n<p>Vyriausyb\u0117 nusprend\u0117 \u0161iuo pasi\u016blymu pasinaudoti.<br \/>\n<span lang=\"LT\">Papildomos vakcinos Lietuv\u0105 tur\u0117t\u0173 pasiekti antroje kit\u0173 met\u0173 pus\u0117je.<\/span><\/p>\n<p>Lietuva jau yra \u012fsigijusi 1<span lang=\"LT\">,<\/span>24 mln. \u201eBioNTech<span lang=\"LT\">\u201c ir<\/span> <span lang=\"LT\">\u201e<\/span>Pfizer\u201c dozi\u0173, taip pat turi sudariusi sutartis su dar penkiais kitais vakcinos vystytojais.<\/p>\n<p><span lang=\"LT\">Skiepijant su \u201e<\/span>BioNTech<span lang=\"LT\">\u201c ir<\/span> <span lang=\"LT\">\u201e<\/span>Pfizer\u201c <span lang=\"LT\">vakcinomis reikia dviej\u0173 dozi\u0173 vienam asmeniui, tod\u0117l su papildomai perkamomis vakcinomis b\u016bt\u0173 galima paskiepyti apie <\/span><span lang=\"EN-US\">300 t<\/span><span lang=\"LT\">\u016bkst. \u017emoni\u0173.<\/span><\/p>\n<p><em><span lang=\"LT\">SAM Spaudos tarnyba<\/span><\/em><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antradien\u012f vakare Vyriausyb\u0117s pasitarime nuspr\u0119sta papildomai \u012fsigyti vakcin\u0173 nuo koronaviruso (COVID-19 ligos). Lietuva papildomai \u012fsigis 616 t\u016bkst. vakcinos dozi\u0173. Europos Komisija pateik\u0117 pasi\u016blym\u0105 valstyb\u0117ms \u012fsigyti papildom\u0105 Vokietijos farmacijos kompanijos \u201eBioNTech\u201c ir jos JAV partner\u0117s \u201ePfizer\u201c vakcin\u0173 dozi\u0173 kiek\u012f. Kiekvienai valstybei narei tenkantis kiekis nustatomas pagal vadinam\u0105j\u012f pro rata princip\u0105. Pagal \u0161\u012f metod\u0105 Lietuva \u012fgijo galimyb\u0119&hellip;<\/p>\n","protected":false},"author":3,"featured_media":17544,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[100],"tags":[],"class_list":["post-17739","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-del-covid-19","category-100","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-4C7","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2020\/12\/18289_e97a5b46e4aade80d4f561215497eaa2.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/17739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/comments?post=17739"}],"version-history":[{"count":2,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/17739\/revisions"}],"predecessor-version":[{"id":17741,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/17739\/revisions\/17741"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/media\/17544"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/media?parent=17739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/categories?post=17739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/tags?post=17739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}